Cargando…
Evaluation of a Novel Tc-99m Labelled Vitamin B(12) Derivative for Targeting Escherichia coli and Staphylococcus aureus In Vitro and in an Experimental Foreign-Body Infection Model
PURPOSE: Vitamin B(12) (cyanocobalamin, Cbl) is accumulated by rapidly replicating prokaryotic and eukaryotic cells. We investigated the potential of a Tc-99m labelled Cbl derivative ([(99m)Tc]PAMA(4)-Cbl) for targeting infections caused by Escherichia coli and Staphylococcus aureus. In vitro bindin...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4641156/ https://www.ncbi.nlm.nih.gov/pubmed/25860122 http://dx.doi.org/10.1007/s11307-015-0832-x |
_version_ | 1782400148628832256 |
---|---|
author | Baldoni, Daniela Waibel, Robert Bläuenstein, Peter Galli, Filippo Iodice, Violetta Signore, Alberto Schibli, Roger Trampuz, Andrej |
author_facet | Baldoni, Daniela Waibel, Robert Bläuenstein, Peter Galli, Filippo Iodice, Violetta Signore, Alberto Schibli, Roger Trampuz, Andrej |
author_sort | Baldoni, Daniela |
collection | PubMed |
description | PURPOSE: Vitamin B(12) (cyanocobalamin, Cbl) is accumulated by rapidly replicating prokaryotic and eukaryotic cells. We investigated the potential of a Tc-99m labelled Cbl derivative ([(99m)Tc]PAMA(4)-Cbl) for targeting infections caused by Escherichia coli and Staphylococcus aureus. In vitro binding assays were followed by biodistribution studies in a mouse model of foreign body infection. PROCEDURES: E. coli (ATCC 25922) and S. aureus (ATCC 43335) were used as test strains. [(57)Co]Cbl, [(67)Ga]citrate and [(99m)Tc]DTPA served as reference compounds. The in vitro competitive binding of [(57)Co]Cbl or [(99m)Tc]PAMA(4)-Cbl, and unlabeled Cbl, to viable or killed bacteria, was evaluated at 37 and 4 °C. A cage mouse model of infection was used for biodistribution of intravenous [(57)Co]Cbl and [(99m)Tc]PAMA(4)-Cbl in cage and dissected tissues of infected and non-infected mice. RESULTS: Maximum binding (mean ± SD) of [(57)Co]Cbl to viable E. coli was 81.7 ± 2.6 % and to S. aureus 34.0 ± 6.7 %, at 37 °C; no binding occurred to heat-killed bacteria. Binding to both test strains was displaced by 100- to 1000-fold excess of unlabeled Cbl. The in vitro binding of [(99m)Tc]PAMA(4)-Cbl was 100-fold and 3-fold lower than the one of [(57)Co]Cbl for E. coli and S. aureus, respectively. In vivo, [(99m)Tc]PAMA(4)-Cbl showed peak percentage of injected dose (% ID) values between 1.33 and 2.3, at 30 min post-injection (p.i.). Significantly higher retention occurred in cage fluids infected with S. aureus at 4 h and with E. coli at 8 h p.i. than in non-infected animals. Accumulation into infected cages was also higher than the one of [(99m)Tc]DTPA, which showed similar biodistribution in infected and sterile mice. [(57)Co]Cbl gradually accumulated in cages with peaks % ID between 3.58 and 4.83 % achieved from 24 to 48 h. Discrimination for infection occurred only in E. coli-infected mice, at 72 h p.i. [(67)Ga]citrate, which showed a gradual accumulation into cage fluids during 12 h, was discriminative for infection from 48 to 72 h p.i. (P < 0.05). CONCLUSION: Cbl displayed rapid and specific in vitro binding to test strains. [(99m)Tc]PAMA(4)-Cbl was rapidly cleared from most tissues and discriminated between sterile and infected cages, being a promising candidate for imaging infections in humans. |
format | Online Article Text |
id | pubmed-4641156 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-46411562015-11-13 Evaluation of a Novel Tc-99m Labelled Vitamin B(12) Derivative for Targeting Escherichia coli and Staphylococcus aureus In Vitro and in an Experimental Foreign-Body Infection Model Baldoni, Daniela Waibel, Robert Bläuenstein, Peter Galli, Filippo Iodice, Violetta Signore, Alberto Schibli, Roger Trampuz, Andrej Mol Imaging Biol Research Article PURPOSE: Vitamin B(12) (cyanocobalamin, Cbl) is accumulated by rapidly replicating prokaryotic and eukaryotic cells. We investigated the potential of a Tc-99m labelled Cbl derivative ([(99m)Tc]PAMA(4)-Cbl) for targeting infections caused by Escherichia coli and Staphylococcus aureus. In vitro binding assays were followed by biodistribution studies in a mouse model of foreign body infection. PROCEDURES: E. coli (ATCC 25922) and S. aureus (ATCC 43335) were used as test strains. [(57)Co]Cbl, [(67)Ga]citrate and [(99m)Tc]DTPA served as reference compounds. The in vitro competitive binding of [(57)Co]Cbl or [(99m)Tc]PAMA(4)-Cbl, and unlabeled Cbl, to viable or killed bacteria, was evaluated at 37 and 4 °C. A cage mouse model of infection was used for biodistribution of intravenous [(57)Co]Cbl and [(99m)Tc]PAMA(4)-Cbl in cage and dissected tissues of infected and non-infected mice. RESULTS: Maximum binding (mean ± SD) of [(57)Co]Cbl to viable E. coli was 81.7 ± 2.6 % and to S. aureus 34.0 ± 6.7 %, at 37 °C; no binding occurred to heat-killed bacteria. Binding to both test strains was displaced by 100- to 1000-fold excess of unlabeled Cbl. The in vitro binding of [(99m)Tc]PAMA(4)-Cbl was 100-fold and 3-fold lower than the one of [(57)Co]Cbl for E. coli and S. aureus, respectively. In vivo, [(99m)Tc]PAMA(4)-Cbl showed peak percentage of injected dose (% ID) values between 1.33 and 2.3, at 30 min post-injection (p.i.). Significantly higher retention occurred in cage fluids infected with S. aureus at 4 h and with E. coli at 8 h p.i. than in non-infected animals. Accumulation into infected cages was also higher than the one of [(99m)Tc]DTPA, which showed similar biodistribution in infected and sterile mice. [(57)Co]Cbl gradually accumulated in cages with peaks % ID between 3.58 and 4.83 % achieved from 24 to 48 h. Discrimination for infection occurred only in E. coli-infected mice, at 72 h p.i. [(67)Ga]citrate, which showed a gradual accumulation into cage fluids during 12 h, was discriminative for infection from 48 to 72 h p.i. (P < 0.05). CONCLUSION: Cbl displayed rapid and specific in vitro binding to test strains. [(99m)Tc]PAMA(4)-Cbl was rapidly cleared from most tissues and discriminated between sterile and infected cages, being a promising candidate for imaging infections in humans. Springer US 2015-04-10 2015 /pmc/articles/PMC4641156/ /pubmed/25860122 http://dx.doi.org/10.1007/s11307-015-0832-x Text en © The Author(s) 2015 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Research Article Baldoni, Daniela Waibel, Robert Bläuenstein, Peter Galli, Filippo Iodice, Violetta Signore, Alberto Schibli, Roger Trampuz, Andrej Evaluation of a Novel Tc-99m Labelled Vitamin B(12) Derivative for Targeting Escherichia coli and Staphylococcus aureus In Vitro and in an Experimental Foreign-Body Infection Model |
title | Evaluation of a Novel Tc-99m Labelled Vitamin B(12) Derivative for Targeting Escherichia coli and Staphylococcus aureus In Vitro and in an Experimental Foreign-Body Infection Model |
title_full | Evaluation of a Novel Tc-99m Labelled Vitamin B(12) Derivative for Targeting Escherichia coli and Staphylococcus aureus In Vitro and in an Experimental Foreign-Body Infection Model |
title_fullStr | Evaluation of a Novel Tc-99m Labelled Vitamin B(12) Derivative for Targeting Escherichia coli and Staphylococcus aureus In Vitro and in an Experimental Foreign-Body Infection Model |
title_full_unstemmed | Evaluation of a Novel Tc-99m Labelled Vitamin B(12) Derivative for Targeting Escherichia coli and Staphylococcus aureus In Vitro and in an Experimental Foreign-Body Infection Model |
title_short | Evaluation of a Novel Tc-99m Labelled Vitamin B(12) Derivative for Targeting Escherichia coli and Staphylococcus aureus In Vitro and in an Experimental Foreign-Body Infection Model |
title_sort | evaluation of a novel tc-99m labelled vitamin b(12) derivative for targeting escherichia coli and staphylococcus aureus in vitro and in an experimental foreign-body infection model |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4641156/ https://www.ncbi.nlm.nih.gov/pubmed/25860122 http://dx.doi.org/10.1007/s11307-015-0832-x |
work_keys_str_mv | AT baldonidaniela evaluationofanoveltc99mlabelledvitaminb12derivativefortargetingescherichiacoliandstaphylococcusaureusinvitroandinanexperimentalforeignbodyinfectionmodel AT waibelrobert evaluationofanoveltc99mlabelledvitaminb12derivativefortargetingescherichiacoliandstaphylococcusaureusinvitroandinanexperimentalforeignbodyinfectionmodel AT blauensteinpeter evaluationofanoveltc99mlabelledvitaminb12derivativefortargetingescherichiacoliandstaphylococcusaureusinvitroandinanexperimentalforeignbodyinfectionmodel AT gallifilippo evaluationofanoveltc99mlabelledvitaminb12derivativefortargetingescherichiacoliandstaphylococcusaureusinvitroandinanexperimentalforeignbodyinfectionmodel AT iodicevioletta evaluationofanoveltc99mlabelledvitaminb12derivativefortargetingescherichiacoliandstaphylococcusaureusinvitroandinanexperimentalforeignbodyinfectionmodel AT signorealberto evaluationofanoveltc99mlabelledvitaminb12derivativefortargetingescherichiacoliandstaphylococcusaureusinvitroandinanexperimentalforeignbodyinfectionmodel AT schibliroger evaluationofanoveltc99mlabelledvitaminb12derivativefortargetingescherichiacoliandstaphylococcusaureusinvitroandinanexperimentalforeignbodyinfectionmodel AT trampuzandrej evaluationofanoveltc99mlabelledvitaminb12derivativefortargetingescherichiacoliandstaphylococcusaureusinvitroandinanexperimentalforeignbodyinfectionmodel |